{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:32:05Z","timestamp":1789122725990,"version":"build-2803163510"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82574963"],"award-info":[{"award-number":["82574963"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014137","name":"Shanghai Shenkang Hospital Development Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014137","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.semnephrol.2026.151718","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:16:09Z","timestamp":1788779769000},"page":"151718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Traditional Chinese Medicine Research in Chronic Kidney Disease: Challenges and Future Perspectives"],"prefix":"10.1016","author":[{"given":"Xueling","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Cijiang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4759-3758","authenticated-orcid":false,"given":"Yifei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.semnephrol.2026.151718_bib0001","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","article-title":"Chronic kidney disease and the global public health agenda: an international consensus","volume":"20","author":"Francis","year":"2024","journal-title":"Nat Rev Nephrol"},{"issue":"10518","key":"10.1016\/j.semnephrol.2026.151718_bib0002","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(25)01853-7","article-title":"Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151718_bib0003","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl (2011)"},{"issue":"4s","key":"10.1016\/j.semnephrol.2026.151718_bib0004","first-page":"S117","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"15","key":"10.1016\/j.semnephrol.2026.151718_bib0005","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semnephrol.2026.151718_bib0006","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in Patients with Chronic Kidney Disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.semnephrol.2026.151718_bib0007","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.semnephrol.2026.151718_bib0008","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/CIRCULATIONAHA.118.036418","article-title":"Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease","volume":"138","author":"Mann","year":"2018","journal-title":"Circulation"},{"issue":"10417","key":"10.1016\/j.semnephrol.2026.151718_bib0009","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.semnephrol.2026.151718_bib0010","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/ki.2013.276","article-title":"Therapeutic use of traditional Chinese herbal medications for chronic kidney diseases","volume":"84","author":"Zhong","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2026.151718_bib0011","article-title":"Global research progress and trends in traditional Chinese medicine for chronic kidney disease since the 21st century: a bibliometric analysis","volume":"11","author":"Wang","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151718_bib0012","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13643-023-02446-4","article-title":"Renal-protective effects of Chinese medicinal herbs and compounds for diabetic kidney disease in animal models: protocol for systematic review and meta-analysis","volume":"13","author":"Liu","year":"2024","journal-title":"Syst Rev"},{"issue":"3","key":"10.1016\/j.semnephrol.2026.151718_bib0013","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/14737167.2024.2306805","article-title":"Meta-analysis of traditional Chinese medicine on chronic kidney disease","volume":"24","author":"Wang","year":"2024","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"10.1016\/j.semnephrol.2026.151718_bib0014","doi-asserted-by":"crossref","first-page":"112","DOI":"10.7326\/M16-2977","article-title":"CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration","volume":"167","author":"Cheng","year":"2017","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151718_bib0015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11655-018-2999-x","article-title":"Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018)","volume":"25","author":"Dai","year":"2019","journal-title":"Chin J Integr Med"},{"issue":"3","key":"10.1016\/j.semnephrol.2026.151718_bib0016","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jep.2011.12.009","article-title":"Optimized project of traditional Chinese medicine in treating chronic kidney disease stage 3: a multicenter double-blinded randomized controlled trial","volume":"139","author":"Wang","year":"2012","journal-title":"J Ethnopharmacol"},{"issue":"28","key":"10.1016\/j.semnephrol.2026.151718_bib0017","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007448","article-title":"Beneficial effects of Fu-Zheng-Qu-Zhuo oral liquid combined with standard integrated therapy in patients with chronic kidney disease (stage 3-4): A randomized placebo-controlled clinical trial","volume":"96","author":"Li","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.semnephrol.2026.151718_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2025.119575","article-title":"A randomized, double-blind, placebo-controlled trial of Wenshenyang decoction for the improvement of renal function and kidney-yang deficiency syndrome in patients with CKD","volume":"348","author":"Jin","year":"2025","journal-title":"J Ethnopharmacol"},{"issue":"5","key":"10.1016\/j.semnephrol.2026.151718_bib0019","article-title":"Efficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: a multicenter double-blinded randomized placebo-controlled trial","volume":"10","author":"Li","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2026.151718_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.157551","article-title":"Efficacy and safety of Chaihuang Tongluo oral liquid in patients with chronic kidney disease: A single-center, randomized, open-label, controlled trial","volume":"149","author":"Congcong","year":"2025","journal-title":"Phytomedicine"},{"issue":"2","key":"10.1016\/j.semnephrol.2026.151718_bib0021","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.joim.2021.01.009","article-title":"Efficacy and safety of Shenyankangfu Tablet, a Chinese patent medicine, for primary glomerulonephritis: A multicenter randomized controlled trial","volume":"19","author":"Wu","year":"2021","journal-title":"J Integr Med"},{"issue":"20","key":"10.1016\/j.semnephrol.2026.151718_bib0022","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.4103\/0366-6999.216407","article-title":"Efficacy and Safety of Niaoduqing Particles for Delaying Moderate-to-severe Renal Dysfunction: A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study","volume":"130","author":"Zheng","year":"2017","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"10.1016\/j.semnephrol.2026.151718_bib0023","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s11655-018-2998-y","article-title":"Effects of Niaoduqing Particles on Delaying Progression of Renal Dysfunction: A Post-trial, Open-Label, Follow-up Study","volume":"25","author":"Zheng","year":"2019","journal-title":"Chin J Integr Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151718_bib0024","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.ajkd.2014.01.431","article-title":"Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial","volume":"64","author":"Zhang","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151718_bib0025","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1080\/13880209.2024.2345080","article-title":"Yi-Shen-Hua-Shi regulates intestinal microbiota dysbiosis and protects against proteinuria in patients with chronic kidney disease: a randomized controlled study","volume":"62","author":"Dong","year":"2024","journal-title":"Pharm Biol"},{"issue":"6","key":"10.1016\/j.semnephrol.2026.151718_bib0026","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1053\/j.ajkd.2013.05.005","article-title":"Efficacy and safety of traditional chinese medicine (Shenqi particle) for patients with idiopathic membranous nephropathy: a multicenter randomized controlled clinical trial","volume":"62","author":"Chen","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1016\/j.semnephrol.2026.151718_bib0027","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ki.2012.486","article-title":"Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy","volume":"83","author":"Kanigicherla","year":"2013","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.semnephrol.2026.151718_bib0028","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2215\/CJN.0000000000000199","article-title":"Add-on Rehmannia-6-Based Chinese Medicine in Type 2 Diabetes and CKD: A Multicenter Randomized Controlled Trial","volume":"18","author":"Chan","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2026.151718_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155457","article-title":"Add-on astragalus in type 2 diabetes and chronic kidney disease: A multi-center, assessor-blind, randomized controlled trial","volume":"130","author":"Chan","year":"2024","journal-title":"Phytomedicine"},{"issue":"10","key":"10.1016\/j.semnephrol.2026.151718_bib0030","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1093\/ndt\/gfad037","article-title":"The effect of micro-particle curcumin on chronic kidney disease progression: the MPAC-CKD randomized clinical trial","volume":"38","author":"Weir","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151718_bib0031","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10787-016-0296-x","article-title":"Impact of extended ginsenoside Rb1 on early chronic kidney disease: a randomized, placebo-controlled study","volume":"25","author":"Xu","year":"2017","journal-title":"Inflammopharmacology"},{"issue":"24","key":"10.1016\/j.semnephrol.2026.151718_bib0032","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.semnephrol.2026.151718_bib0033","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.semnephrol.2026.151718_bib0034","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-024-03169-2","article-title":"The traditional Chinese medicine Qiliqiangxin in heart failure with reduced ejection fraction: a randomized, double-blind, placebo-controlled trial","volume":"30","author":"Cheang","year":"2024","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.semnephrol.2026.151718_bib0035","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2026.151718_bib0036","article-title":"Multi-omics approaches for deciphering the complexity of traditional Chinese medicine syndromes in stroke: A systematic review","volume":"13","author":"Liu","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.semnephrol.2026.151718_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(25)00672-5","article-title":"CONSORT 2025 statement: updated guideline for reporting randomised trials","author":"Hopewell","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2026.151718_bib0038","article-title":"Natural products in traditional Chinese medicine for renal fibrosis: a comprehensive review","volume":"16","author":"Zhao","year":"2025","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.semnephrol.2026.151718_bib0039","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1159\/000443115","article-title":"HuangQi Decoction Ameliorates Renal Fibrosis via TGF-\u03b2\/Smad Signaling Pathway In Vivo and In Vitro","volume":"38","author":"Zhao","year":"2016","journal-title":"Cell Physiol Biochem"},{"issue":"3","key":"10.1016\/j.semnephrol.2026.151718_bib0040","first-page":"507","article-title":"Efficacy of Danggui Buxue decoction on diabetic nephropathy-induced renal fibrosis in rats and possible mechanism","volume":"43","author":"Ye","year":"2023","journal-title":"J Tradit Chin Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151718_bib0041","article-title":"Renoprotective effect of Zhenwu decoction against renal fibrosis by regulation of oxidative damage and energy metabolism disorder","volume":"8","author":"Li","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.semnephrol.2026.151718_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2025.156548","article-title":"TaoHeChengQi Decotion alleviate chronic renal failure via regulation of PHD2\/UCP1 and RIPK3\/AKT\/TGF-beta pathway","volume":"141","author":"Liu","year":"2025","journal-title":"Phytomedicine"},{"key":"10.1016\/j.semnephrol.2026.151718_bib0043","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jep.2019.02.044","article-title":"A patent herbal drug Yi-Shen-Hua-Shi granule ameliorates C-BSA-induced chronic glomerulonephritis and inhabits TGFbeta signaling in rats","volume":"236","author":"Zhao","year":"2019","journal-title":"J Ethnopharmacol"},{"issue":"3","key":"10.1016\/j.semnephrol.2026.151718_bib0044","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s13577-017-0192-8","article-title":"Acetylshikonin from Zicao ameliorates renal dysfunction and fibrosis in diabetic mice by inhibiting TGF-beta1\/Smad pathway","volume":"31","author":"Li","year":"2018","journal-title":"Hum Cell"},{"issue":"6","key":"10.1016\/j.semnephrol.2026.151718_bib0045","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrneph.2016.48","article-title":"TGF-\u03b2: the master regulator of fibrosis","volume":"12","author":"Meng","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2026.151718_bib0092","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s11596-020-2255-4","article-title":"Shenkang VII Recipe Attenuates Unilateral Ureteral Obstruction-induced Renal Fibrosis via TGF-\u03b2\/Smad, NF-\u03baB and SHH Signaling Pathway","volume":"40","author":"Zhou","year":"2020","journal-title":"Curr Med Sci"},{"key":"10.1016\/j.semnephrol.2026.151718_bib0046","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/9705948","article-title":"ShenKang Injection Attenuates Renal Fibrosis by Inhibiting EMT and Regulating the Wnt\/\u03b2-Catenin Pathway","volume":"2022","author":"Wei","year":"2022","journal-title":"Evidence-Based Complementary and Alternative Medicine"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151718_bib0047","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1097\/IMNA-D-24-00040","article-title":"Qi-Huang-Yi-Shen Formula Alleviate Tubular Epithelial-Mesenchymal Transition in Diabetic Kidney Disease Through HIF-1a\/snail Signaling Pathway","volume":"12","author":"Yang","year":"2025","journal-title":"Integrative Medicine in Nephrology and Andrology"},{"key":"10.1016\/j.semnephrol.2026.151718_bib0048","article-title":"Yishen-Huoxue formula alleviates renal interstitial fibrosis by attenuating hypoxia-induced renal cell injury and promoting angiogenesis via miR-210\/HIF-1\u03b1 pathway","volume":"10","author":"Du","year":"2025","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151718_bib0049","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/kisup.2014.20","article-title":"Hypoxia and fibrosis in chronic kidney disease: crossing at pericytes","volume":"4","author":"Kawakami","year":"2014","journal-title":"Kidney Int Suppl (2011)"},{"issue":"6","key":"10.1016\/j.semnephrol.2026.151718_bib0050","doi-asserted-by":"crossref","first-page":"F1409","DOI":"10.1152\/ajprenal.00380.2019","article-title":"Macrophage polarization in chronic kidney disease: a balancing act between renal recovery and decline?","volume":"317","author":"Engel","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151718_bib0051","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1080\/0886022X.2022.2079525","article-title":"Berberine protects diabetic nephropathy by suppressing epithelial-to-mesenchymal transition involving the inactivation of the NLRP3 inflammasome","volume":"44","author":"Ma","year":"2022","journal-title":"Ren Fail"},{"key":"10.1016\/j.semnephrol.2026.151718_bib0052","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/1173324","article-title":"Mechanisms of Kidney Cell Pyroptosis in Chronic Kidney Disease and the Effects of Traditional Chinese Medicine","volume":"2021","author":"Ding","year":"2021","journal-title":"Evid Based Complement Alternat Med"},{"issue":"6","key":"10.1016\/j.semnephrol.2026.151718_bib0053","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1159\/000362974","article-title":"Down-regulation of PERK-ATF4-CHOP pathway by Astragaloside IV is associated with the inhibition of endoplasmic reticulum stress-induced podocyte apoptosis in diabetic rats","volume":"33","author":"Chen","year":"2014","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.semnephrol.2026.151718_bib0054","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.2147\/DDDT.S167405","article-title":"Emodin mitigates podocytes apoptosis induced by endoplasmic reticulum stress through the inhibition of the PERK pathway in diabetic nephropathy","volume":"12","author":"Tian","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.semnephrol.2026.151718_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/mmr.2020.11641","article-title":"Berberine alleviates palmitic acid\u2011induced podocyte apoptosis by reducing reactive oxygen species\u2011mediated endoplasmic reticulum stress","volume":"23","author":"Xiang","year":"2021","journal-title":"Mol Med Rep"},{"issue":"3","key":"10.1016\/j.semnephrol.2026.151718_bib0056","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1097\/IMNA-D-24-00018","article-title":"New Insights into the Use of Traditional Chinese Medicine for Treating Diabetic Kidney Disease by Regulating DNA Methylation","volume":"11","author":"Ma","year":"2024","journal-title":"Integrative Medicine in Nephrology and Andrology"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151718_bib0057","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbadis.2014.11.006","article-title":"Novel curcumin analog C66 prevents diabetic nephropathy via JNK pathway with the involvement of p300\/CBP-mediated histone acetylation","volume":"1852","author":"Wang","year":"2015","journal-title":"Biochim Biophys Acta"},{"issue":"7","key":"10.1016\/j.semnephrol.2026.151718_bib0058","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s11655-023-3564-9","article-title":"Curcumin Interferes with TGF- \u03b2 1-Induced Fibrosis in NRK-49F Cells by Reversing ADAMTS18 Gene Methylation","volume":"30","author":"Xu","year":"2024","journal-title":"Chin J Integr Med"},{"issue":"6","key":"10.1016\/j.semnephrol.2026.151718_bib0059","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.joim.2020.08.006","article-title":"Fuzheng Huayu recipe, a traditional Chinese compound herbal medicine, attenuates renal interstitial fibrosis via targeting the miR-21\/PTEN\/AKT axis","volume":"18","author":"Wang","year":"2020","journal-title":"J Integr Med"},{"key":"10.1016\/j.semnephrol.2026.151718_bib0060","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/ijms25137130","article-title":"Research Progress of Pyroptosis in Diabetic Kidney Disease","volume":"25","author":"Fan","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"Pt B","key":"10.1016\/j.semnephrol.2026.151718_bib0061","article-title":"Sanqi qushi formula ameliorates podocyte injury in membranous nephropathy by inhibiting endoplasmic reticulum stress-induced ferroptosis","volume":"353","author":"Sun","year":"2025","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.semnephrol.2026.151718_bib0062","article-title":"mTOR-mediated nutrient sensing and oxidative stress pathways regulate autophagy: a key mechanism for traditional Chinese medicine to improve diabetic kidney disease","volume":"16","author":"Li","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.semnephrol.2026.151718_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110241","article-title":"Salvianolic acid B attenuates epithelial-mesenchymal transition in renal fibrosis rats through activating Sirt1-mediated autophagy","volume":"128","author":"He","year":"2020","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151718_bib0064","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nm.3762","article-title":"Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development","volume":"21","author":"Kang","year":"2015","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.semnephrol.2026.151718_bib0065","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/2211-5463.13568","article-title":"Metabolic reprogramming heterogeneity in chronic kidney disease","volume":"13","author":"Miguel","year":"2023","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.semnephrol.2026.151718_bib0066","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cells9010044","article-title":"TRPC Channels in Proteinuric Kidney Diseases","volume":"9","author":"Hall","year":"2019","journal-title":"Cells"},{"issue":"24","key":"10.1016\/j.semnephrol.2026.151718_bib0067","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202503532R","article-title":"Cellular Senescence in Kidney Diseases: From Bench to Clinic","volume":"39","author":"Shu","year":"2025","journal-title":"Faseb j"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151718_bib0068","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1097\/IMNA-D-24-00051","article-title":"Therapeutic Effects of Quercetin on Renal Fibrosis and Injury","volume":"12","author":"Wang","year":"2025","journal-title":"Integrative Medicine in Nephrology and Andrology"},{"issue":"17","key":"10.1016\/j.semnephrol.2026.151718_bib0069","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.2174\/0113892010276372231129105022","article-title":"Icariin Attenuates Human Renal Tubular Epithelial Cell Senescence by Targeting PAK2 via miR-23b-3p","volume":"25","author":"Zhang","year":"2024","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.semnephrol.2026.151718_bib0070","article-title":"Unraveling the mysteries of the gut-kidney axis: the protective role of traditional Chinese medicine in chronic kidney disease","volume":"16","author":"Li","year":"2025","journal-title":"Front Microbiol"},{"key":"10.1016\/j.semnephrol.2026.151718_bib0071","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.780924","article-title":"Rhubarb Enema Decreases Circulating Trimethylamine N-Oxide Level and Improves Renal Fibrosis Accompanied With Gut Microbiota Change in Chronic Kidney Disease Rats","volume":"12","author":"Ji","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.semnephrol.2026.151718_bib0072","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1896781","article-title":"Rhubarb Enema Increasing Short-Chain Fatty Acids that Improves the Intestinal Barrier Disruption in CKD May Be Related to the Regulation of Gut Dysbiosis","volume":"2022","author":"Ji","year":"2022","journal-title":"Biomed Res Int"},{"issue":"14","key":"10.1016\/j.semnephrol.2026.151718_bib0073","doi-asserted-by":"crossref","first-page":"17468","DOI":"10.18632\/oncotarget.8160","article-title":"Emodin via colonic irrigation modulates gut microbiota and reduces uremic toxins in rats with chronic kidney disease","volume":"7","author":"Zeng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semnephrol.2026.151718_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110325","article-title":"Tangshen formula modulates gut Microbiota and reduces gut-derived toxins in diabetic nephropathy rats","volume":"129","author":"Zhao","year":"2020","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"10.1016\/j.semnephrol.2026.151718_bib0075","doi-asserted-by":"crossref","first-page":"5625","DOI":"10.1080\/21655979.2021.2023789","article-title":"Shenqi Yanshen Formula (SQYSF) protects against chronic kidney disease by modulating gut microbiota","volume":"13","author":"Zhang","year":"2022","journal-title":"Bioengineered"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151718_bib0076","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4062\/biomolther.2024.142","article-title":"Natural Compounds in Kidney Disease: Therapeutic Potential and Drug Development","volume":"33","author":"Natesan","year":"2025","journal-title":"Biomol Ther (Seoul)"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151718_bib0077","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13020-023-00836-3","article-title":"Quality evaluation methods of chinese medicine based on scientific supervision: recent research progress and prospects","volume":"18","author":"Chen","year":"2023","journal-title":"Chin Med"},{"key":"10.1016\/j.semnephrol.2026.151718_bib0078","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/ph18040538","article-title":"Trends and Pitfalls in the Progress of Network Pharmacology Research on Natural Products","volume":"18","author":"Panossian","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.semnephrol.2026.151718_bib0079","article-title":"A critical assessment of Traditional Chinese Medicine databases as a source for drug discovery","volume":"15","author":"Wang","year":"2024","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.semnephrol.2026.151718_bib0080","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s11655-023-3629-9","article-title":"Challenges and Perspectives in Target Identification and Mechanism Illustration for Chinese Medicine","volume":"29","author":"Guo","year":"2023","journal-title":"Chin J Integr Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151718_bib0081","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s13020-025-01269-w","article-title":"Holistic concept guided quality control of traditional Chinese medicines for optimizing bioavailability","volume":"20","author":"Tian","year":"2025","journal-title":"Chin Med"},{"issue":"Suppl 3","key":"10.1016\/j.semnephrol.2026.151718_bib0082","doi-asserted-by":"crossref","DOI":"10.1590\/0001-3765201920190105","article-title":"The role of natural products in modern drug discovery","volume":"91","author":"Calixto","year":"2019","journal-title":"An Acad Bras Cienc"},{"issue":"3","key":"10.1016\/j.semnephrol.2026.151718_bib0083","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","article-title":"Natural products in drug discovery: advances and opportunities","volume":"20","author":"Atanasov","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.semnephrol.2026.151718_bib0084","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.cell.2011.08.024","article-title":"Artemisinin: discovery from the Chinese herbal garden","volume":"146","author":"Miller","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.semnephrol.2026.151718_bib0085","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/7942614","article-title":"Establishing a Cell-Based High-Content Screening Assay for TCM Compounds with Anti-Renal Fibrosis Effects","volume":"2018","author":"Wang","year":"2018","journal-title":"Evid Based Complement Alternat Med"},{"issue":"6","key":"10.1016\/j.semnephrol.2026.151718_bib0086","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","article-title":"A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles","volume":"171","author":"Subramanian","year":"2017","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.semnephrol.2026.151718_bib0087","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2337\/db20-0580","article-title":"Connectivity Mapping Identifies BI-2536 as a Potential Drug to Treat Diabetic Kidney Disease","volume":"70","author":"Zhang","year":"2021","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151718_bib0088","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.kint.2020.01.029","article-title":"Connectivity mapping of a chronic kidney disease progression signature identified lysine deacetylases as novel therapeutic targets","volume":"98","author":"Williams","year":"2020","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.semnephrol.2026.151718_bib0089","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1681\/ASN.2012060590","article-title":"Renoprotective effect of combined inhibition of angiotensin-converting enzyme and histone deacetylase","volume":"24","author":"Zhong","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2026.151718_bib0090","first-page":"5","article-title":"Herb-CMap: a multimodal fusion framework for deciphering the mechanisms of action in traditional Chinese medicine using Suhuang antitussive capsule as a case study","volume":"25","author":"Wang","year":"2024","journal-title":"Brief Bioinform"},{"issue":"1","key":"10.1016\/j.semnephrol.2026.151718_bib0091","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1038\/s41467-019-12433-w","article-title":"Arctigenin attenuates diabetic kidney disease through the activation of PP2A in podocytes","volume":"10","author":"Zhong","year":"2019","journal-title":"Nat Commun"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929526000379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929526000379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:37:40Z","timestamp":1789119460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929526000379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":92,"alternative-id":["S0270929526000379"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2026.151718","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Traditional Chinese Medicine Research in Chronic Kidney Disease: Challenges and Future Perspectives","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2026.151718","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"151718"}}